Abiomed (ABMD) Receives Consensus Rating of “Buy” from Brokerages

Shares of Abiomed (NASDAQ:ABMD) have received an average rating of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $309.50.

Several research analysts have commented on the stock. Goldman Sachs assumed coverage on shares of Abiomed in a report on Wednesday, April 4th. They issued a “buy” rating and a $332.00 price target for the company. Zacks Investment Research raised shares of Abiomed from a “hold” rating to a “strong-buy” rating and set a $335.00 price target for the company in a report on Tuesday, April 3rd. ValuEngine raised shares of Abiomed from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. SunTrust Banks reissued a “buy” rating and issued a $370.00 price target on shares of Abiomed in a report on Friday, February 16th. Finally, BTIG Research reissued a “hold” rating on shares of Abiomed in a report on Sunday, February 4th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:ABMD opened at $290.93 on Wednesday. Abiomed has a one year low of $123.60 and a one year high of $309.28. The firm has a market capitalization of $13,400.68, a price-to-earnings ratio of 248.66, a PEG ratio of 2.97 and a beta of 0.17.

Abiomed (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.20. Abiomed had a net margin of 16.58% and a return on equity of 15.54%. The firm had revenue of $154.00 million during the quarter, compared to the consensus estimate of $154.00 million. During the same period last year, the firm earned $0.34 EPS. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. equities research analysts anticipate that Abiomed will post 2.25 earnings per share for the current year.

In other news, VP Andrew J. Greenfield sold 20,000 shares of Abiomed stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total transaction of $5,407,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank lifted its holdings in shares of Abiomed by 2.4% during the 4th quarter. Swiss National Bank now owns 71,300 shares of the medical equipment provider’s stock worth $13,362,000 after acquiring an additional 1,700 shares during the last quarter. Pratt Collard Advisory Partners LLC bought a new stake in shares of Abiomed during the 4th quarter worth $412,000. Franklin Resources Inc. lifted its holdings in shares of Abiomed by 21.2% during the 4th quarter. Franklin Resources Inc. now owns 328,717 shares of the medical equipment provider’s stock worth $61,619,000 after acquiring an additional 57,560 shares during the last quarter. Hamilton Lane Advisors LLC lifted its holdings in shares of Abiomed by 50.8% during the 4th quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock worth $4,356,000 after acquiring an additional 7,827 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Abiomed by 46.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 919 shares during the period. 88.39% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/25/abiomed-abmd-receives-consensus-rating-of-buy-from-brokerages.html.

About Abiomed

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.

Analyst Recommendations for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply